Therapeutics Pipeline

Qualigen has a diverse portfolio of proprietary oncology product candidates:
Program: Indication Development Pre-IND Phase 1 Phase 2
AS1411: Acute Myeloid Leukemia (AML)
AS1411: Renal Cell (Kidney)
AS1411: Pancreatic
ALAN: Acute Myeloid Leukemia (AML)
ALAN: Neuroblastoma
ALAN: Pancreatic
ALAN-RE: Radiation Enhancement-Breast (Triple Negative)
ALAN-CE: Contrast Enhancement-Solid Tumors
STARS: All types
RAS-F: Pancreatic
RAS-F: Lung
RAS-F: Colorectal